Wells syndrome in a patient receiving adalimumab biosimilar: A case report and review of literature
Sir, Wells syndrome was first described by George Wells in 1971 as a recurrent granulomatous dermatitis with eosinophilia. 1 It presents with erythematous, indurated, tender or mildly pruritic plaques which mimic cellulitis. Demonstration of dermal edema, marked eosinophil infiltration and presence of free eosinophilic granules coating collagen bundles ("flame figures") in histopathology is diagnostic. 1, 2 A 36-year-old man with a 12-year history of hidradenitis suppurativa (Hurley's grade III) was started on adalimumab biosimilar (Exemptia; Zydus Cadila) monotherapy because of inadequate treatment response to multiple courses of antibiotics and retinoids (acitretin 35 mg/day for 1 year and 3 months). He presented to the outpatient department with three erythematous to plum colored indurated plaques of recent onset on the third and fifth digits of the right hand and sole of the right foot, 1 month after starting adalimumab biosimilar (6 hours after third dose) [ . He also complained of minimal pain that exacerbated with the movement of the fingers and on walking. There was no history of any other drug intake, fever, trauma, recent travel, insect bite or intravenous drug use. Sweet's syndrome, Wells syndrome and fixed drug eruption were considered as differential diagnoses.
A complete blood count revealed increased white blood cell count (13.37 × 10 3 /dL [normal 4.00 × 10 3 /dL to 11.00 × 10 3 / dL]) and peripheral eosinophilia (18.6%) with an absolute eosinophil count of 2.48 × 10 3 /dL (normal 0.10 × 10 3 /dL to 0.50 × 10 3 /dL). C-reactive protein levels (6.9 mg/L [normal 0 mg/L to 5.0 mg/L]) and ESR (70 mm/h) were found to be elevated, suggesting an inflammatory process. Total serum IgE 65 U/ml (2-100 U/ml), renal and liver function were normal. No ova or parasites were observed in stool microscopy. The clinical diagnosis of Wells syndrome was confirmed by the typical histopathological finding of marked eosinophil infiltration into the dermis and subcutaneous tissue with flame figures [Figures 4 and 5] . A short course of oral steroids, i.e. prednisolone 40 mg for 2 weeks, gradually tapered over the next 8 weeks led to disease resolution [ Figure 6 ]. Drug rechallenge test elicited similar results within 5 hours of giving the fourth dose. Adalimumab biosimilar was stopped and there has been no recurrence of the lesions thus far.
Wells syndrome presents with sudden onset, single or multiple, erythematous, indurated or urticarial plaques which resolve without scarring over 2-8 weeks. Clinical variants of Wells syndrome include plaque type, annular granuloma-like, urticaria-like, papulo-vesicular, bullous, papulo-nodular and fixed drug eruption-like lesions. 2 In our case, plaque-type lesions were seen. The pathogenesis is not very clear and it is believed to be a hypersensitivity reaction to a variety of exogenous and endogenous stimuli. Excessive production of interleukin-5 resulting in eosinophil accumulation and a local Th2 immune response has been documented. Wells syndrome is associated with infections (viral/parasitic/arthropod bite), malignancy, atopy, Churg-Strauss syndrome and drugs. Table 1 lists the iatrogenic causes of Wells syndrome. 2 Adalimumab-induced Sweet's syndrome, erythema multiforme and fixed drug eruption have been reported previously but the characteristic histopathology helped us in clinching the diagnosis.
Some cases of eosinophilia associated with tumor necrosis factor-α inhibitors have been reported before. 3 Wells syndrome-like lesions have been described at the injection site of etanercept 4 and adalimumab 5 as local reaction to the drug, but not away from the injection site as observed in our patient. The Naranjo adverse drug probability score was 9 in our patient, suggestive of a definite adverse drug reaction [ Table 2 ]. A Medline and PubMed search was performed and we recorded the features in cases of Wells syndrome or cases with blood or tissue eosinophilia after anti-tumor necrosis factor-α therapy [ Table 3 ]. [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] The mechanism of tumor necrosis factor-α inhibition leading to eosinophilia remains still elusive. Anti-tumor necrosis factor-α agents can induce an immune deviation from the Th1 to the Th2 phenotype in some patients, resulting in eosinophilia. Quaglino et al. reported that psoriasis patients responding to etanercept showed a significant reversal of the Th1/Th17 activation and a concomitant upregulation of Th2 and regulatory T cells. 16 Formation of IgE-class-switched antibodies can lead to IgE-mediated drug hypersensitivity and subsequent eosinophilia. 17 More sustained and effective tumor necrosis factor -α inhibition was associated with a higher risk of eosinophilia. Hence, adalimumab has more risk of causing eosinophilia than etanercept. Recently, Chiriac et al. reported a case series of 28 patients who developed eosinophilia during the first 6 months with adalimumab therapy. 18 To conclude, the introduction of biologics has significantly improved treatment efficacy in several chronic inflammatory diseases. Recent reports suggest that tumor necrosis factor-α inhibitors can cause both blood and tissue eosinophilia. In most cases, it is benign and does not warrant drug withdrawal. However, reports of acute necrotizing eosinophilic myocarditis 8 and lung damage 15 due to tissue eosinophilia caused by tumor necrosis factor inhibitors also exist. It is important for the treating dermatologists to recognize this complication early and treat accordingly. With new biologics entering the market every year, it is vital to identify and report potential drug-related side effects.
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B. WHO-UMC causality category
Temporal relation to drug intake Certain
Response to withdrawal
Event definitive pharmacologically or phenomenologically (recognized pharmacological phenomenon)
Rechallenge positive
Cannot be explained by disease or other drugs
C. Modified Hartwig and Siegel Scale
The AR required that treatment with the suspected drug be discontinued, or changed Level 3 (moderate)
An antidote or other treatment (prednisolone) was required UMC: Uppsala Monitoring Centre, AR: Adverse reaction 
